Tag: investor

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- WeRide Inc. (“WeRide” or the “Company”) (NASDAQ: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced that each of the proposed resolutions submitted for shareholders’ approval (the “Proposed Resolutions”) as set forth in the notice of the annual general meeting dated May 8, 2026, Beijing time (the “AGM Notice”), has been adopted at the annual general meeting held in Guangzhou, Guangdong Province, China today.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of UP Fintech Holding Limited (NASDAQ: TIGR) resulting from allegations that UP Fintech may have issued materially misleading business information to the investing public.

INDIANAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, today announced the completion of the sale of City Center, a multi-level mixed-use asset in White Plains, New York, for gross proceeds of $50 million.

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

INDIANAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, announced today the release of its annual Corporate Responsibility Report, which provides a comprehensive overview of the Company's strategy, initiatives, and progress across its corporate responsibility practices and policies.

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.